Not found

Paul Webb, PhD

Full Affiliate Member, Research Institute
Houston Methodist


After completion of his fellowship in the Metabolic Research Unit at the University of California at San Francisco (UCSF) in 1994, Dr. Webb joined the permanent research staff there in the laboratory of Dr. John Baxter. He rose through the ranks and, in 1999, became an Assistant Research Biochemist Level IV. In 2001, Dr. Webb joined the Diabetes Center at UCSF where he was quickly promoted to an Associate Researcher Level IV. He spent a year as a visiting professor in Biochemistry at the University of San Francisco in 2005 where he taught several courses in biochemistry. He has co-written over 130 manuscripts that have been published in peer-reviewed publications.

Description of Research

Dr. Webb's main research interests are investigations into the principles of nuclear hormone receptor structure and function, as well as studies of the actions of pharmaceutical agents to selectively modulate actions of these proteins. Research approaches include X-ray structural analysis, targeted mutagenesis to understand receptor structure, detailed analysis of gene expression and genome wide sequence interactions and collaborative studies to determine the metabolic effects of drugs in preclinical models.

Areas Of Expertise

Diabetes Nuclear hormone receptor Ligand design
Education & Training

Postdoctoral Fellowship, Immunology Department, University of California, San Francisco, CA
PhD, Imperial Cancer Research Fund, London University, London
Postdoctoral Fellowship, Metabolic Research Unit, University of California, San Francisco, CA
MA, Pembroke College, Oxford University

HBO1 directs histone H4 specific acetylation, potentiating mechano-transduction pathways and membrane elasticity in ovarian cancer cells
Quintela, M, Sieglaff, DH, Gazze, AS, Zhang, A, Gonzalez, D, Francis, L, Webb, P & Conlan, RS 2019, Nanomedicine: Nanotechnology, Biology, and Medicine, vol. 17, pp. 254-265.

Protein disulfide isomerase modulates the activation of thyroid hormone receptors
Campos, JLO, Doratioto, TR, Videira, NB, Ribeiro Filho, HV, Batista, FAH, Fattori, J, Indolfo, NDC, Nakahira, M, Bajgelman, MC, Cvoro, A, Laurindo, FRM, Webb, P & Figueira, ACM 2019, Frontiers in Endocrinology, vol. 10, no. JAN.

Development of 5N-Bicalutamide, a High-Affinity Reversible Covalent Antiandrogen
De Jesus Cortez, F, Nguyen, P, Truillet, C, Tian, B, Kuchenbecker, KM, Evans, MJ, Webb, P, Jacobson, MP, Fletterick, RJ & England, PM 2017, ACS Chemical Biology, vol. 12, no. 12, pp. 2934-2939.

Somatic loss of estrogen receptor beta and p53 synergize to induce breast tumorigenesis
Bado, I, Nikolos, F, Rajapaksa, G, Wu, W, Castaneda, J, Krishnamurthy, S, Webb, P, Gustafsson, J-A & Thomas, C 2017, Breast Cancer Research, vol. 19, no. 1, 79.

3,5-diodothyronine (3,5-T2) Reduces Blood Glucose Independently of Insulin Sensitization in Obese Mice
Teixeira, SDS, Filgueira, CS, Sieglaff, DH, Benod, C, Villagomez, R, Minze, LJ, Zhang, A, Webb, P & Nunes, MT 2016, Acta physiologica (Oxford, England).

Ligand independent and subtype-selective actions of thyroid hormone receptors in human adipose derived stem cells
Cvoro, A, Bajic, A, Zhang, A, Simon, M, Golic, I, Sieglaff, DH, Maletic-Savatic, M, Korac, A & Webb, P 2016, PLoS ONE, vol. 11, no. 10, e0164407.

Sustained zero-order delivery of GC-1 from a nanochannel membrane device alleviates metabolic syndrome
Filgueira, CS, Nicolov, E, Hood, RL, Ballerini, A, Garcia-Huidobro, J, Lin, JZ, Fraga, D, Webb, P, Sabek, O, Gaber, AO, Phillips, KJ & Grattoni, A 2016, International Journal of Obesity.

Structural dataset for the PPAR? V290M mutant
Puhl, AC, Webb, P & Polikarpov, I 2016, Data in Brief, vol. 7, pp. 1430-1437.

Gustafsson, J-A & Webb, P 2016, Journal of Steroid Biochemistry and Molecular Biology, vol. 157, pp. 1-2.

TLX: An elusive receptor
Benod, C, Villagomez, R & Webb, P 2016, Journal of Steroid Biochemistry and Molecular Biology, vol. 157, pp. 41-47.

Sobetirome: The past, present and questions about the future
Lammel Lindemann, J & Webb, P 2016, Expert Opinion on Therapeutic Targets, vol. 20, no. 2, pp. 145-149.

Pharmacophore elucidation of phosphoiodyn A - Potent and selective peroxisome proliferator-activated receptor ß/d agonists with neuroprotective activity
Kinarivala, N, Suh, JH, Botros, M, Webb, P & Trippier, PC 2016, Bioorganic and Medicinal Chemistry Letters.

Pharmacological Activation of Thyroid Hormone Receptors Elicits a Functional Conversion of White to Brown Fat
Lin, JZ, Martagón, AJ, Cimini, SL, Gonzalez, DD, Tinkey, DW, Biter, A, Baxter, JD, Webb, P, Gustafsson, J-A, Hartig, SM & Phillips, KJ 2015, Cell Reports, vol. 13, no. 8, pp. 1528-1537.

Similarities and distinctions in actions of surface-directed and classic androgen receptor antagonists
Suh, JH, Chattopadhyay, A, Sieglaff, DH, Samaniego, CS, Cox, MB & Webb, P 2015, PLoS ONE, vol. 10, no. 9, e0137103.

The FKBP52 Cochaperone Acts in Synergy with ß-Catenin to Potentiate Androgen Receptor Signaling
Samaniego, CS, Suh, JH, Chattopadhyay, A, Olivares, K, Guy, N, Sivils, JC, Dey, P, Yumoto, F, Fletterick, RJ, Strom, AM, Gustafsson, J-A, Webb, P & Cox, MB 2015, PLoS ONE, vol. 10, no. 7, e0134015.

Correction: Estrogen receptor ß2 induces hypoxia signature of gene expression by stabilizing HIF-1a in prostate cancer
Dey, P, Velazquez-Villegas, LA, Faria, M, Turner, A, Jonsson, P, Webb, P, Williams, C, Gustafsson, J-A & Ström, AM 2015, PLoS ONE, vol. 10, no. 6, e0132085.

PPAR? partial agonist GQ-16 strongly represses a subset of genes in 3T3-L1 adipocytes
Milton, FA, Cvoro, A, Amato, AA, Sieglaff, DH, Filgueira, CS, Arumanayagam, AS, De Lima, MDCA, Pitta, IR, De Assis Rocha Neves, F & Webb, P 2015, Biochemical and Biophysical Research Communications, vol. 464, no. 3, 34219, pp. 718-723.

Estrogen receptor ß2 induces hypoxia signature of gene expression by stabilizing HIF-1a in prostate cancer
Dey, P, Velazquez-Villegas, LA, Faria, M, Turner, A, Jonsson, P, Webb, P, Williams, C, Gustafsson, J-A & Ström, AM 2015, PLoS ONE, vol. 10, no. 5, e0128239.

The amelioration of hepatic steatosis by thyroid hormone receptor agonists is insufficient to restore insulin sensitivity in ob/ob mice
Martagón, AJ, Lin, JZ, Cimini, SL, Webb, P & Phillips, KJ 2015, PLoS ONE, vol. 10, no. 4, e0122987.

Silencing LRH-1 in colon cancer cell lines impairs proliferation and alters gene expression programs
Bayrer, JR, Mukkamala, S, Sablin, EP, Webb, P & Fletterick, RJ 2015, Proceedings of the National Academy of Sciences of the United States of America, vol. 112, no. 8, pp. 2467-2472.

Live Chat Available